Login to Your Account

Weekly Dosing in Reach?

'Baxter' the Wall: Biogen/Sobi Data Weighed in Hemophilia A

By Randy Osborne
Staff Writer

Thursday, November 1, 2012
With safety and efficacy endpoints met in the Phase III trial testing Biogen Idec Inc.'s long-lasting rFVIIIFc (recombinant Factor VIII Fc fusion protein) for hemophilia A, investors were scrutinizing the candidate's odds in a market led by Advate, the serum-free, recombinant Factor VIII therapy from Baxter Healthcare Corp.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription